A strong launch, with little room for error
- MYQORZO is now on the market in the U.S. and Europe for obstructive hypertrophic cardiomyopathy, a heart muscle disease.
- Second-quarter sales grew rapidly, reaching $25.3 million globally as doctors prescribed the drug to 1,500 patients.
- Positive Phase 3 data in non-obstructive HCM could expand aficamten into a much larger patient group.
- International expansion is underway, starting with a launch in Germany and upcoming approvals in the UK.
- The stock depends heavily on one drug, so launch speed, patent litigation, and FDA reviews matter a lot.
Aficamten carries the story
Cytokinetics has crossed a big line. It is no longer only a drug developer. MYQORZO, also called aficamten, started U.S. commercial sales in January 2026 for symptomatic obstructive hypertrophic cardiomyopathy, or oHCM. The launch is moving fast. In the second quarter of 2026, the drug produced $25.3 million of total net product revenue and was dispensed to 1,500 patients.
The latest clinical news makes the bull case stronger. In May 2026, Cytokinetics reported positive top-line Phase 3 data from ACACIA-HCM in non-obstructive HCM, or nHCM. Management plans to submit a supplemental FDA filing in the fourth quarter of 2026. If regulators agree with the data, MYQORZO could become the first therapy approved across the full HCM spectrum.
That creates a clear upside path. The company must keep growing U.S. oHCM sales, file for the nHCM expansion, succeed in Germany, and collect future value from partners in China and Japan. The pipeline also gives the company shots on goal beyond aficamten, including omecamtiv mecarbil and ulacamten.
The catch is price and execution. The stock is already being judged like MYQORZO will become a massive success. Finn's view is more cautious because valuation and financial health scores are very low. If payors slow access, doctors stay with older choices, patent litigation cuts economics, or the nHCM filing disappoints, the story can break quickly.
A new drug launch funds the lab
Cytokinetics makes money mainly from MYQORZO product sales. Right now, those sales are concentrated in the U.S., but international revenue is starting to arrive. The European launch began in Germany in June 2026, which added $2.3 million from initial distributor purchases. Approvals in the UK will soon open another market.
The company also earns license, milestone, and collaboration revenue from partners. Sanofi controls aficamten rights in Greater China. Bayer holds the rights for Japan. In the second quarter of 2026, collaboration revenues brought in $3.3 million.
This is still an expensive business. Cytokinetics is funding a global commercial rollout, late-stage trials, and earlier research at the same time. The company has used royalty agreements, convertible notes, term loans, and a large May 2026 capital raise to support the plan. Those tools buy time, but they do not remove the need for MYQORZO sales to scale and cover the bills.
One approved drug, several heart bets
MYQORZO® (aficamten) for oHCM
MYQORZO is an oral cardiac myosin inhibitor approved for symptomatic obstructive HCM. U.S. sales began in January 2026, making it the company's first commercial product.
Aficamten for nHCM
Positive Phase 3 ACACIA-HCM data opened the path to a planned fourth-quarter FDA filing in non-obstructive HCM. Approval would widen the addressable market and could make aficamten the first approved therapy for the full HCM spectrum.
Omecamtiv mecarbil
Omecamtiv mecarbil is a cardiac myosin activator in development for heart failure with severely reduced ejection fraction. A new Phase 3 trial called COMET-HF is ongoing.
Ulacamten
Ulacamten is a next-generation cardiac myosin inhibitor being tested in heart failure with preserved ejection fraction. It is in the Phase 2 AMBER-HFpEF trial.
CK-089
CK-089 is a fast skeletal muscle troponin activator in Phase 1. It could be used in muscular dystrophy or other diseases where muscle function is impaired.
Q2 revenue shows the product shift
Cytokinetics reports one operating segment, but second-quarter 2026 revenue shows a clear shift toward product sales as the MYQORZO launch accelerates.
What can go wrong
MYQORZO launch stalls
High impact · Medium oddsCytokinetics depends heavily on MYQORZO becoming a large product. Early demand was strong and captured more than 40 percent of new prescriptions. However, if payors add friction, doctors wait to switch patients, or the early group of willing patients runs out, revenue growth could flatten.
FDA view on nHCM is less favorable
High impact · Medium oddsThe ACACIA-HCM top-line result is the biggest positive change in the thesis. The open question is how complete the full data look and how the FDA views the filing package. A slower review, request for more data, or narrow label would hurt the market expansion case.
Patent litigation cuts economics
High impact · Medium oddsBMS and Myokardia are an important overhang because an unfavorable patent outcome could force royalties, a settlement, or other limits. That would matter more as MYQORZO grows. EU patent opposition proceedings are another legal watch item for Europe.
Cash burn stays high
High impact · High oddsThe roughly $700 million May raise gave Cytokinetics more time. Still, the company is funding sales teams, European infrastructure, and several clinical programs. If MYQORZO sales do not ramp fast enough, future financing could dilute shareholders or add debt.
Single-source manufacturing fails
High impact · Low oddsCytokinetics relies on outside manufacturers and has no internal manufacturing capacity for MYQORZO. A supply problem with the active ingredient or finished tablets could interrupt launch momentum. This risk is common in biotech, but it is sharper when one product drives the story.
In one breath
What does Cytokinetics do?
Cytokinetics develops drugs that change how muscle proteins work. Its first approved product is MYQORZO for obstructive hypertrophic cardiomyopathy, a disease where the heart muscle becomes too thick and can block blood flow.
Why did the Cytokinetics thesis improve in 2026?
MYQORZO started selling in the U.S. and produced $25.3 million of total net product revenue by the second quarter. In addition, aficamten posted positive Phase 3 data in non-obstructive HCM.
Is Cytokinetics profitable?
No. The company still has a history of major losses and high spending. The launch gives it a path to product revenue, but MYQORZO needs to grow a lot before the business can support its research and commercial costs.
What are the next big dates for CYTK?
Investors are watching for full ACACIA-HCM data in August 2026, the nHCM supplemental NDA submission in the fourth quarter, and the November 14, 2026 PDUFA date for the MAPLE-HCM label update.
